-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Significant Decrease in Short Interest
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Significant Decrease in Short Interest
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) was the target of a significant decrease in short interest in August. As of August 15th, there was short interest totalling 9,340,000 shares, a decrease of 18.5% from the July 31st total of 11,460,000 shares. Based on an average trading volume of 9,320,000 shares, the days-to-cover ratio is currently 1.0 days.
Hedge Funds Weigh In On Akebia Therapeutics
A number of hedge funds have recently modified their holdings of AKBA. Point72 Hong Kong Ltd purchased a new position in shares of Akebia Therapeutics during the fourth quarter valued at $30,000. BNP Paribas Arbitrage SA grew its holdings in shares of Akebia Therapeutics by 123.7% during the second quarter. BNP Paribas Arbitrage SA now owns 90,540 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 50,066 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Akebia Therapeutics during the first quarter valued at $39,000. Mirabella Financial Services LLP purchased a new position in shares of Akebia Therapeutics during the first quarter valued at $40,000. Finally, MetLife Investment Management LLC boosted its position in Akebia Therapeutics by 176.6% during the first quarter. MetLife Investment Management LLC now owns 85,186 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 54,389 shares during the last quarter. 55.34% of the stock is currently owned by institutional investors and hedge funds.
Get Akebia Therapeutics alerts:Wall Street Analyst Weigh In
AKBA has been the topic of several recent analyst reports. StockNews.com assumed coverage on Akebia Therapeutics in a report on Saturday. They issued a "hold" rating on the stock. HC Wainwright lowered their target price on Akebia Therapeutics from $2.00 to $1.25 in a research note on Monday, May 16th. Seven analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $1.75.
Akebia Therapeutics Stock Performance
Shares of NASDAQ AKBA traded down $0.01 during mid-day trading on Monday, hitting $0.37. The company had a trading volume of 1,700,878 shares, compared to its average volume of 8,553,613. The stock has a market cap of $67.47 million, a price-to-earnings ratio of -0.39 and a beta of 1.50. Akebia Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.35. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.30 and a quick ratio of 1.15. The firm's 50 day simple moving average is $0.40 and its two-hundred day simple moving average is $0.87.Akebia Therapeutics (NASDAQ:AKBA – Get Rating) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.23 earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.54. Akebia Therapeutics had a negative return on equity of 197.12% and a negative net margin of 55.04%. The firm had revenue of $126.76 million for the quarter, compared to the consensus estimate of $49.10 million. During the same quarter in the previous year, the business earned ($0.51) EPS. As a group, equities research analysts forecast that Akebia Therapeutics will post -0.44 earnings per share for the current year.
Akebia Therapeutics Company Profile
(Get Rating)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
Recommended Stories
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- What is the NASDAQ Stock Exchange?
- Should You Be Bullish On Barrick Gold?
- The Institutions Choose Dollar General For The 2nd Half
- The S&P 500 Just Flashed A Significant Signal
- Why Trading Volume is Unusually High on These 3 Stocks
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) was the target of a significant decrease in short interest in August. As of August 15th, there was short interest totalling 9,340,000 shares, a decrease of 18.5% from the July 31st total of 11,460,000 shares. Based on an average trading volume of 9,320,000 shares, the days-to-cover ratio is currently 1.0 days.
木通治疗公司(纳斯达克:AKBA-GET评级)是8月份空头股数大幅下降的目标。截至8月15日,空头股数共有934万股,比7月31日的1146万股减少了18.5%。以9,320,000股的平均成交量计算,目前天数与回补比率为1.0天。
Hedge Funds Weigh In On Akebia Therapeutics
对冲基金对木通治疗公司的看法
A number of hedge funds have recently modified their holdings of AKBA. Point72 Hong Kong Ltd purchased a new position in shares of Akebia Therapeutics during the fourth quarter valued at $30,000. BNP Paribas Arbitrage SA grew its holdings in shares of Akebia Therapeutics by 123.7% during the second quarter. BNP Paribas Arbitrage SA now owns 90,540 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 50,066 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Akebia Therapeutics during the first quarter valued at $39,000. Mirabella Financial Services LLP purchased a new position in shares of Akebia Therapeutics during the first quarter valued at $40,000. Finally, MetLife Investment Management LLC boosted its position in Akebia Therapeutics by 176.6% during the first quarter. MetLife Investment Management LLC now owns 85,186 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 54,389 shares during the last quarter. 55.34% of the stock is currently owned by institutional investors and hedge funds.
多家对冲基金最近调整了对AKBA的持有量。Point72 Hong Kong Ltd在第四季度购买了价值3万美元的木通治疗公司的新股票头寸。法国巴黎银行套利公司在第二季度持有的木通治疗公司股票增加了123.7%。法国巴黎银行套利公司现在拥有90,540股这家生物制药公司的股票,价值32,000美元,在上个季度又购买了50,066股。GSA Capital Partners LLP在第一季度购买了木通治疗公司新的股票头寸,价值3.9万美元。Mirabella Financial Services LLP在第一季度购买了木通治疗公司新的股票头寸,价值40,000美元。最后,大都会人寿投资管理公司在第一季度将其在木通治疗公司的头寸增加了176.6%。大都会人寿投资管理有限责任公司现在拥有85,186股这家生物制药公司的股票,价值61,000美元,在上个季度又购买了54,389股。55.34%的股票目前由机构投资者和对冲基金持有。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
AKBA has been the topic of several recent analyst reports. StockNews.com assumed coverage on Akebia Therapeutics in a report on Saturday. They issued a "hold" rating on the stock. HC Wainwright lowered their target price on Akebia Therapeutics from $2.00 to $1.25 in a research note on Monday, May 16th. Seven analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $1.75.
AKBA一直是最近几份分析师报告的主题。StockNews.com在周六的一份报告中承担了对木通治疗公司的报道。他们对该股的评级为“持有”。在5月16日星期一的一份研究报告中,HC Wainwright将他们对木通治疗公司的目标价从2.00美元下调至1.25美元。根据MarketBeat.com的数据,七位分析师对该股的评级为持有,目前该股的平均评级为“持有”,共识目标价为1.75美元。
Akebia Therapeutics Stock Performance
木通治疗公司股票表现
Akebia Therapeutics (NASDAQ:AKBA – Get Rating) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.23 earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.54. Akebia Therapeutics had a negative return on equity of 197.12% and a negative net margin of 55.04%. The firm had revenue of $126.76 million for the quarter, compared to the consensus estimate of $49.10 million. During the same quarter in the previous year, the business earned ($0.51) EPS. As a group, equities research analysts forecast that Akebia Therapeutics will post -0.44 earnings per share for the current year.
木通治疗公司(纳斯达克代码:AKBA-GET评级)最近一次公布收益结果是在8月4日星期四。这家生物制药公司公布本季度每股收益为0.23美元,比普遍预期的0.31美元高出0.54美元。木通治疗公司的净资产回报率为负197.12%,净利润率为负55.04%。该公司本季度营收为1.2676亿美元,而市场普遍预期为4910万美元。在去年同一季度,该业务实现每股收益(0.51美元)。作为一个整体,股票研究分析师预测,木通治疗公司本年度的每股收益将为0.44美元。
Akebia Therapeutics Company Profile
木通治疗公司简介
(Get Rating)
(获取评级)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
木通治疗公司是一家生物制药公司,专注于肾脏疾病患者治疗药物的开发和商业化。该公司的主要研究产品候选产品是vadustat,这是一种口服疗法,正处于第三阶段开发,用于治疗依赖透析和非透析依赖的成年患者的慢性肾脏疾病(CKD)引起的贫血。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- What is the NASDAQ Stock Exchange?
- Should You Be Bullish On Barrick Gold?
- The Institutions Choose Dollar General For The 2nd Half
- The S&P 500 Just Flashed A Significant Signal
- Why Trading Volume is Unusually High on These 3 Stocks
- 免费获取StockNews.com关于木通治疗的研究报告(AKBA)
- 什么是纳斯达克证券交易所?
- 你应该看好巴里克·戈尔德吗?
- 机构选择美元通货作为下半年
- 标准普尔500指数刚刚发出了一个重要信号
- 这三只股票的成交量为何异常高
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受木通治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对木通治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧